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Edited by Gianni CesareniAbstract The DNA-binding protein recombination signal-bind-
ing protein-Jk (RBP-J) plays a key role in transcriptional regu-
lation by targeting the intracellular domain of Notch (NIC) and
the Epstein–Barr virus nuclear antigen 2 (EBNA2) to speciﬁc
promoters. In the absence of the Notch signaling, RBP-J acts
as a transcriptional suppressor through recruiting co-suppressors
such as histone deacetylase (HDAC). KyoT2 is a LIM domain
protein that suppresses the RBP-J-mediated transcriptional acti-
vation. In the current study, we show that the polycomb group
(PcG) protein HPC2, which functions as a transcriptional sup-
pressor, is a candidate of KyoT2-binding proteins. To conﬁrm
the physical and functional interaction between KyoT2 and
HPC2, we carried out yeast two-hybrid, GST-pull down, co-
immunoprecipitation, as well as mammalian two-hybrid assays.
Our results showed HPC2 and KyoT2 interacted both in vitro
and in vivo, probably through the C-terminal fragment of
HPC2 and LIM domains of KyoT2. In addition, we also found
that overexpression of HPC2, not only inhibited transactivation
of a RBP-J-dependent promoter by NIC, but also transactiva-
tion by RBP-J–VP16, a constitutively active form of RBP-J.
Taken together, our results suggested that KyoT2 might inhibit
the RBP-J-mediated transactivation through NIC by recruiting
co-suppressors such as HPC2.
 2005 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The Notch signaling pathway is an evolutionarily conserved
pathway participating in cell fate determination steps in devel-
opment (reviewed in [1]). Notch was identiﬁed in Drosophila
decades ago and encodes a type I transmembrane protein
receptor that contains multiple structural motifs. The extracel-
lular domain of Notch contains 36 EGF-like repeats and 3Abbreviations: RBP-J, recombination signal-binding protein-Jk; NIC,
intracellular domain of Notch; EBNA2, Epstein–Barr virus nuclear
antigen 2; PcG, polycomb group; HDAC, histone deacetylase; cDNA,
complementary DNA; RT-PCR, reverse transcription polymerase
chain reaction
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RAM (recombination signal-binding protein-Jk (RBP-J)-asso-
ciating molecule) domain, 6 ankyrin/CDC10 repeats, nuclear
localization sequences, a transactivation domain, and a C-ter-
minal PEST domain. Genetic and biochemical analyses have
demonstrated that when Notch is triggered by association with
its ligands, a proteolysis reaction occurs within the transmem-
brane domain of the receptor, and the intracellular domain of
Notch (NIC) is released. The released NIC translocates into
the nuclear and serves as a transcriptional activator of down-
stream genes. However, because NIC does not possess a
DNA-binding activity, it requires a DNA-binding protein,
Su (H) (Suppressor of Hairless) in Drosophila and RBP-J in
mammals, to mediate its transcriptional activation activity
[1,2]. In mammals, although multiple members of Notch fam-
ily (Notch 1–4 in human and mouse) and their ligands (Delta1
and Jagged1 and 2 in mouse) have been identiﬁed, evidence has
shown that RBP-J is the intranuclear target of all four types of
the Notch receptors [3,4].
RBP-J recognizes a consensus sequence C/TGTGGGAA
that exists in multiple diﬀerentiation-regulating genes such as
members of the mouse Hes (Hairy and enhancer of split) fam-
ily [5]. NIC activates promoters recognized by RBP-J through
replacement of transcriptional suppressors by the CDC10/
ankyrin repeats, and through recruitment of two conserved
histone acetyltransferases, PCAF (p300/CBP-associated fac-
tor) and GCN5, by the internal transactivation domain located
downstream to the CDC10/ankyrin repeats [6,7]. In addition
to NIC, RBP-J also mediates transactivation of the Epstein–
Barr (EB) virus nuclear antigen 2 (EBNA2), a crucial molecule
involved in cell immortalization and transformation by the EB
virus [8,9].
On the other hand, in the absence of transactivators like
NIC or EBNA2, RBP-J functions as a transcriptional suppres-
sor [10]. Multiple molecules have been proposed to participate
in the transcriptional suppression by RBP-J, such as histone
deacetylase (HDAC), SMRT/N-CoR (silencing mediator for
retinoid and thyroid receptor/nuclear receptor co-repressor),
CIR (CBF1 interacting co-repressor), SAP30, and MINT
(MSX2-interacting nuclear target protein) [11–16]. Although,
these molecules have been identiﬁed to negatively regulate
Notch signaling, however, the molecular mechanism of the
RBP-J-mediated transcriptional suppression is still elusive.
KyoT2 is a LIM domain protein and interacts with RBP-J
through a binding motif on its C-terminus generated by alter-
native mRNA splicing [17]. Previous studies had shown thatblished by Elsevier B.V. All rights reserved.
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RBP-J recognition sites by blocking interaction between
RBP-J and transactivators such as NIC and EBNA2. How-
ever, our recent results have suggested that in addition to act
as a competitor for binding sites, KyoT2 may regulate RBP-J
through its LIM domains, which have been shown to function
as a protein–protein interaction interface [18–20]. Thus,
through interaction with LIM domains of KyoT2, RING1, a
member of the polycomb group (PcG) proteins, might sup-
press transactivation of RBP-J and regulate Notch signaling
during mammalian development [21].
HPC2, another member of the PcG proteins, was also iden-
tiﬁed as a candidate of KyoT-interacting molecule in the yeast
two-hybrid screening [21]. In this study, we investigated the
physical and functional interaction of KyoT2 with HPC2.
We showed that HPC2 physically interacts with KyoT2 both
in vitro and in vivo. Overexpression of HPC2 suppressed
transactivation of an RBP-J-dependent promoter by NIC, as
well as transcription activity of a constitutively active RBP-J,
the RBP-J–VP16 fusion protein. Our data further suggested
that KyoT2 might inhibit the RBP-J-mediated transactivation
by NIC through recruiting HPC2, in addition to RING1.2. Materials and methods
2.1. RT-PCR
The coding sequence of human HPC2 complementary DNA
(cDNA) was ampliﬁed by reverse transcription polymerase chain reac-
tion (RT-PCR) from total RNA of Hela cells using the Trizol reagent
according to the manufacturers instruction (Invitrogen). The primers
used for PCR were 5 0-CCATGGAGCTGCCAGCTGTTGGCGAG-
3 0 and 5 0-CCTCCGGCTACACCGTCACGTACTCC-3 0. The ampli-
ﬁed fragment was cloned into a T-vector (Promega, Germany) and
conﬁrmed by DNA sequencing.
2.2. Yeast two-hybrids assay
All bait plasmids, including pGBKT7–KyoT1, pGBKT7–KyoT2,
pGBKT7–KyoT2–LIM1, and pGBKT7–KyoT2–LIM2, for the yeast
two-hybrid assay were described previously [21]. The full-length HPC2
cDNA was inserted in frame into pGADT7 to construct a prey plasmid
(pGADT7–HPC2). Prey plasmids with truncated HPC2 (pGADT7–
HPC2–N with amino acids 1–374, and pGADT7–HPC2–C with amino
acids 375–588) were generated by restriction digestion and ligation, and
conﬁrmed by sequencing. Plasmids were used to transform the yeast
strain AH109 in combinations as described in the results by the LiAc
method, and grown clones were tested for nutritional phenotypes. Single
clone was tested by liquid b-galactosidase assay for b-galactosidase
activity.
2.3. Cell culture and transfection
HEK293 and 293T cells were maintained in Dulbeccos modiﬁed Ea-
gles Medium (DMEM) supplemented with 10% fetal calf serum
(FCS), 100 U/ml penicillin, 100 lg/ml streptomycin sulfate, and
2 mM L-glutamine (Gibco BRL). Cells were plated onto 6 well plates
at a density of 5 · 105 cells per well and cultured at 37 C with 5%
CO2 overnight for transfection. The transfection was performed at
90% cell conﬂuence with a total amount of 2 lg DNA (for details,
see Section 3) per well using Lipofectamine 2000 (Invitrogen), follow-
ing the manufacturers protocol.
2.4. GST-pull down assay
The GST–KyoT2 fusion protein was produced as described previ-
ously [21]. The coding region of full-length HPC2 cDNA was inserted
into pCMV2-Flag, and the generated plasmid (pCMV2-Flag-HPC2)
was used to transfect 293T cells. Harvested cell extracts were incu-
bated with the puriﬁed GST–KyoT2 or GST (used as a negative con-
trol) protein, respectively, and the protein–protein interaction wasassayed by pulling down with the glutathione–Sepherose beads (Sig-
ma), followed by immunoblotting with an anti-Flag antibody (M2,
Sigma).
2.5. Co-immunoprecipitation
Plasmids pCMV-KyoT2-Myc, pCMV2-Flag-RING1, and pCMV2-
Flag-RBP-J were described previously [21]. Plasmids were transfected
into 293T cells using Lipofectamine 2000 as shown in Section 3. Sixty
hours after transfection, cells were collected and lysed using the phos-
pho-lysis buﬀer (50 mM Tris–Cl, pH 7.5, 150 mMNaCl, 1 mMMgCl2,
0.5% NP40, 1 mg/ml BSA, and 0.1 mM PMSF). Immunopreciptation
was carried out with an anti-Myc (9E10, Santa Cruz) antibody. After
washing extensively with the phospho-lysis buﬀer, co-precipitated pro-
teins were analyzed by SDS–PAGE followed by Western blotting using
the anti-Flag antibody, or antibodies against RBP-J (K0043) [17] (pro-
vided by T. Honjo), HPC2 (a gift from BQ Jin, unpublished), or
RING1 (C-20) (Santa Cruz). Expression of the Myc-tagged proteins
was detected by Western blotting of the cell lysates using the anti-
Myc antibody.
2.6. Reporter assays
For mammalian two-hybrid experiments, the full-length KyoT2
cDNA and HPC2 cDNA were inserted in frame into multiple cloning
sites of pCMX–GAL4–DBD and pCMX–VP16(NLS) (generously
provided by T Honjo), to generate plasmids pCMX–GAL4–DBD–
KyoT2 and pCMX–VP16–HPC2, respectively. The plasmids were
co-transfected with a reporter construct (TK MH100 · 4 luc), in which
the luciferase gene was under control of a promoter containing multi-
ple recognition sites of the GAL4 DNA-binding domain. Cells were
lysed 48 h after transfection with a hypotonic buﬀer (91 mM
K2HPO4, 9 mM KH2PO4, 10% glycerol, 1 mM DTT, 10% Triton X-
100), and the level of the luciferase in cell lysates was examined as de-
scribed. Transfection eﬃciency was calibrated by co-transfection with
pSV-b-gal, followed by examining the b-galactosidase activity in cell
lysates. Each experiment was repeated at least three times and data
were analyzed with the Students t test.
Transactivation of the RBP-J-responsive promoter was detected
using reporter assay with the reporter construct pGa981-6, which con-
tains a hexamerized 50 bp EBNA2 response element of the TP-1 pro-
moter and is strictly dependent on RBP-J [3]. Expression vectors for
KyoT2 (pEFBOS-KyoT2), RING1 (pEFBOS-RING1), HPC2 (pEF-
BOS-HPC2) and NIC (pEFBOS-NIC) were constructed by insertion
of the full-length cDNA of KyoT2, RING1, HPC2, as well as NIC into
pEFBOS-neo vector, respectively. Cells were collected 48 h after trans-
fection with diﬀerent plasmids and the luciferase activity was examined
as above. pSV-b-gal was included in each transfection as an internal
control of the transfection eﬃciency.
2.7. CHIP assays
Chromatin immunoprecipitation (CHIP) assay was carried out using
a kit from Upstate (Milton Keynes, UK) according to the manual pro-
vided by the supplier. Brieﬂy, NIH3T3 cells were transfected with
expression vectors for Myc-NIC or Myc-KyoT2 plus Flag-HPC2, to-
gether with pGa981-6. Forty-eight hours after transfection, cells were
crosslinked with 1% formaldehyde, disrupted and ultra-sonicated.
The cell lysates were immunoprecipitated with anti-Myc, anti-Flag,
or anti-RBP-J, with a preimmune serum as a control. The crosslinking
of the immunoprecipitates were reversed by heating up, and bound
DNA was ampliﬁed using primers to the promoter of pGa981-6 con-
taining RBP-J-recognizing sequence. The sequence of the primers
was 5 0-gtagatcccgactcgtgg-3 0 and 5 0-tttcccacggtgcccttc-3 0. The ampli-
ﬁed fragments were analyzed using 3% agarose gel electrophoresis.3. Results
3.1. KyoT2 interacts with HPC2 through LIM domains in yeast
In a screening of KyoT2-interacting proteins using the yeast
two-hybrid system with KyoT2 as bait [21], we identiﬁed
HPC2 as another candidate of KyoT2-binding proteins. To
conﬁrm the interaction between KyoT2 and HPC2, and to
identify potential domains of KyoT2 and HPC2 responsible
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with full-length KyoT1, KyoT2, and HPC2, as well as their
truncated derivatives (Fig. 1). When full-length KyoT1 or
KyoT2 and diﬀerent truncated HPC2 fragments were used to
transform yeast AH109, positive interactions were detected be-
tween KyoT2 and HPC2 as well as KyoT1 and HPC2, suggest-
ing that KyoT2 interacted with HPC2 through its LIM
domain(s), because KyoT1 contains four LIM domains with-
out an RBP-J-binding motif [17]. This was further conﬁrmed
by yeast two-hybrid assays using single LIM domains (LIM1
or LIM2 from the N-terminal) of KyoT2 as baits. Both of
the LIM domains of KyoT2 showed positive interaction with
HPC2. On the other hand, while the C-terminal fragment of
HPC2 showed strong positive interaction with KyoT2, its N-
terminal fragment showed much weaker interaction with
KyoT2 in yeast. These results indicated that the LIM domains
of KyoT2 and the C-terminal fragment of HPC2 might be
mainly responsible domains for the interaction between
KyoT2 and HPC2 in yeast.
3.2. Physical interaction between KyoT2 and HPC2
Direct in vitro interaction of KyoT2 with HPC2 was veriﬁed
by a GST-pull down assay. The GST and GST–KyoT2 fusion
protein were generated in Escherichia coli and puriﬁed, and
were used to interact with the HPC2 protein expressed by
transfection of cultured 293T cells. As shown in Fig. 2A, a
clear interaction of HPC2 with GST–KyoT2 was observed.
No interaction could be detected between GST and HPC2.
This result suggested that HPC2 directly interacted with
KyoT2.
In vivo interaction of KyoT2 with HPC2 was tested by co-
immunoprecipitation assays. Cultured 293T cells were trans-
fected with expression vectors of the Myc-tagged KyoT2 and
the Flag-tagged HPC2, or the Flag-tagged RBP-J as a positive
control. The KyoT2 protein was immunoprecipitated using an
antibody against the Myc tag. Co-immunoprecipitated pro-
teins were detected by Western blotting using the anti-Flag
antibody. As shown in Fig. 2B, both Flag-HPC2 and Flag-
RBP-J were co-precipitated with Myc-KyoT2. Moreover, we
examined interactions between Myc-tagged KyoT2 and endog-
enous HPC2, as well as endogenous RBP-J and RING1. Cell
lysates from Myc-KyoT2-transfected cells were examined byFig. 1. Identiﬁcation of interaction domains between KyoT2 and HPC2 in y
cloned in the yeast two-hybrid (system 3) vectors were used to transform yeast
examined and was shown. (), 60.25, (+), 0.25–0.50, (++), 0.50–1.00, (+++)Western blotting using anti-RING1, anti-RBP-J, or anti-
HPC2 antibodies. Endogenous RING1, RBP-J, and HPC2
were all detected in the precipitated proteins (Fig. 2C). These
results indicated that HPC2 was able to interact with KyoT2
in vivo.
To further examine whether KyoT2 and HPC2 interact in
mammalian cells, we employed the mammalian two-hybrid as-
say. KyoT2 was fused to the GAL4 DNA-binding domain and
HPC2 was fused to the VP16 transactivation domain, to gen-
erate pCMX–GAL4DBD–KyoT2 and pCMX–VP16–HPC2,
respectively. Then pGAL4DBD–KyoT2 was co-transfected
into HEK-293 cells together with increasing amounts of
pCMX–VP16–HPC2, as well as the reporter plasmid TK
MH100 · 4 luc. Luciferase activity in cell lysates was examined
48 h after transfection. The results showed that, while transfec-
tion only with the GAL4DBD–KyoT2 or VP16–HPC2 expres-
sion vector did not activate expression of the luciferease in
cells, co-transfection of the two vectors stimulated increasingly
higher luciferase activity in cell lysates (Fig. 2D). This result
suggested that KyoT2 and HPC2 interacted in mammalian
cells.
3.3. HPC2 formed a complex with RBP-J through KyoT2 in
cells
Since KyoT2 binds RBP-J through its RBP-J-binding motif
on the C-terminal [17], and binds HPC2 through its LIM do-
mains on the N-terminal as shown above, we questioned
whether HPC2 might form a complex with RBP-J through
KyoT2. To access this question, we tested the formation of a
three-molecule complex of KyoT2, HPC2 and RBP-J in cells
using the co-immunoprecipitation assay. We co-expressed the
Flag-tagged HPC2 and the Flag-tagged RBP-J in 293T cell
with the Myc-tagged KyoT2. Immunoprecipitation was car-
ried out using the anti-Myc antibody 60 h after transfection,
and co-precipitated proteins were detected with the anti-Flag
antibody after Western blotting. As shown in Fig. 3A,
Flag-RBP-J and Flag-HPC2 could be simultaneously co-pre-
cipitated with KyoT2, suggesting that KyoT2, HPC2, and
RBP-J might form a three-molecule complex in cells. In addi-
tion, as we have shown that RING1 also associates with
KyoT2, we looked at if HPC2 and RING1 could bind to
KyoT2 simultaneously by the co-immunoprecipitation experi-east. Full-length or truncated fragments of KyoT2, KyoT1, and HPC2
cells. The b-galactosidase activity in cell lysates from single colonies was
, P 1.00. The ﬁlled block in KyoT2 indicates the RBP-J-binding motif.
Fig. 2. Interaction between KyoT2 and HPC2 in vitro and in vivo. (A) GST-pull down assay. GST and GST–KyoT2 were generated in E. coli and
puriﬁed, and were incubated with Flag-HPC2 expressed in transfected cells. Protein interaction was examined by Western blotting after pulling down
with the glutathione–Sepharose 4B beads. (B) Immunoprecipitation assay. Vectors for expression of the Myc-tagged KyoT2 and the Flag-tagged
HPC2 or the Flag-tagged RBP-J were used to transfect 293T cells. Cell lysates were prepared 60 h after transfection and were immunoprecipitated
with the anti-Myc antibody, followed by Western blotting with the anti-Flag antibody. Lower panel, Western blotting of cell lysates with the anti-
Myc antibody. One-tenth of the cell extract used for immunoprecipitation was run as the input. (C) Immunoprecipitation assay. Cells were
transfected with pCMV-KyoT2-Myc and cell lysates were immunoprecipitated with the anti-myc antibody, followed by Western blotting with anti-
RING1 (left), anti-RBP-J (middle), or anti-HPC2 (right). Myc-tagged KyoT2 in cell lysates was detected using anti-Myc. One-twentieth of the cell
extract used for immunoprecipitation was run as the input. (D) Mammalian two-hybrid assay. HEK-293 cells were co-transfected with expression
vectors of GAL4–DBD–KyoT2 (0.2 lg) and increasing amounts (0.2, 0.4, and 0.8 lg) of expressing vectors of VP16–HPC2 and the luciferase
reporter plasmid (0.4 lg). Luciferase activity was detected in cell lysates 48 h after transfection.
Fig. 3. (A) Co-immunoprecipitation of HPC2, RBP-J, and KyoT2. Expression vectors of the Myc-tagged KyoT2 and the Flag-tagged RBP-J and
HPC2 were used to transfected 293T cells. Cell lysates were prepared 60 h after transfection and were immunoprecipitated with the anti-Myc
antibody. Co-precipitated proteins were detected with the anti-Flag antibody after Western blotting. (B) Co-immunoprecipitation of HPC2, RING1,
and KyoT2. Cells were transfected with expression vectors of the Myc-tagged KyoT2 and the Flag-tagged RING1 and HPC2, and
immunoprecipitation was performed as above. One-tenth of the cell extract used for immunoprecipitation was run as the input.
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could be simultaneously immunoprecipitated with Myc-tagged
KyoT2 (Fig. 3B), suggesting that a ternary complex containing
HPC2, RING1, and KyoT2 be formed in cells.
3.4. HPC2 suppressed transactivation of RBP-J by NIC
Our earlier works have shown that RING1 inhibited the
RBP-J-mediated transactivation by NIC through association
with LIM protein KyoT2 [21]. In the current study, our data
showed that KyoT2 might also recruit HPC2 to RBP-J
through its LIM domains. Because both HPC2 and RING1
are members of the PcG complex and have transcriptional sup-
pression activity, we assumed that HPC2 might also suppress
the RBP-J-mediated transactivation through association with
KyoT2. In order to answer this question, we transfected
HEK293 cells using vectors expressing KyoT2 and/or HPC2,
together with the luciferase reporter plasmid pGa981-6 [3].
The results showed that expression of NIC with pGa981-6
led to strong transcriptional activation. Transactivation of
the RBP-J-dependent promoter was slightly inhibited by low
amount of KyoT2 alone (Fig. 4A) [17,21]. Low amount of
HPC2 also slightly inhibited RBP-J-mediated transactivation
by NIC, suggesting that there is endogenous KyoT2 protein
in transfected cells, as conﬁrmed by RT-PCR (data not
shown). This transactivation was strongly suppressed by co-
expression of HPC2 in a dose-dependent manner in the pres-
ence of KyoT2 (Fig. 4A). Because HPC2 (and RING1) does
not associate directly with RBP-J and suppresses RBP-J (our
unpublished results) [21], these results suggested that KyoT2
might suppress the RBP-J-mediated transcription by recruiting
the PcG protein HPC2.
3.5. KyoT2 suppressed transactivation of the RBP-J-dependent
promoter by RBP-J–VP16
KyoT2 has been shown to suppress transactivation of NIC
by competitively binding to a site on RBP-J. However, our
previous and current work suggested that KyoT2 might alsoFig. 4. HPC2 suppressed transactivation of the RBP-J-dependent promoter
transfected with plasmids expressing NIC (0.2 lg) (A) or RBP-J–VP16 (B), K
plasmid expressing HPC2, together with the TP-1 reporter constructs (0.2 lg)
assay.suppress transcription by recruiting co-suppressors such as
RING1 [21] and HPC2 through its LIM domains. To further
demonstrate this assumption, we tested the eﬀect of HPC2
on transactivation of the RBP-J-dependent promoter by the
constitutively active RBP-J, RBP-J–VP16. As shown in Fig.
4B, in the presence of KyoT2, HPC2 suppressed transactiva-
tion activity of RBP-J–VP16 in a dose-dependent manner.
3.6. KyoT2 and HPC2 bind to the promoter harboring RBP-J
recognition sites
The PcG proteins including HPC2 suppress transcription
through forming large PcG complexes on promoters [22–28].
We employed the CHIP assay to test whether HPC2 could
be recruited to RBP-J-binding promoters through KyoT2.
Cells were transfected with plasmids as well as pGa981-6, as
indicated in Fig. 5, and a CHIP assay was performed using
speciﬁc antibodies. The precipitated DNA was ampliﬁed using
primers targeting the TP-1 promoter sequences recognized by
RBP-J. The results showed that while no positive band was
ampliﬁed when precipitated with a preimmune serum, the
TP-1 promoter sequence was ampliﬁed in precipitates with
anti-Myc-NIC, anti-Myc-KyoT2, anti-Flag-HPC2, as well as
anti-RBP-J (Fig. 5), suggesting that these molecules could
form complexes on the promoter sequence of pGa981-6, the
RBP-J responsible reporter construct.4. Discussion
As the key transcription factor in the Notch signaling path-
way, RBP-J mediates transactivation of all the four Notch
receptors. In the absence of transactivators, RBP-J suppresses
transcription. So far, sophisticated molecular mechanisms
involving multiple co-activators and co-suppressors have been
suggested to explain the transcriptional regulation of RBP-J.
In the current study, we suggested that in addition to other
molecules, PcG protein HPC2 might be another player in theby NIC (A) or constitutively active RBP-J (B). HEK-293 cells were co-
yoT2 (0.1 lg), or/and increasing amounts (0.2, 0.5, and 1.0 lg) of the
. Transactivation of the reporter construct was detected using luciferase
Fig. 5. CHIP assay. Cells were transfected as indicated in Section 2.
Forty-eight hours after transfection, cells were collected and subjected
to CHIP using antibodies indicated. Precipitated DNA fragments were
ampliﬁed by PCR and analyzed using 3% agarose gel electrophoresis.
The ampliﬁed fragment is indicated by an arrow. M, molecular weight
marker, from top, 2000, 1000, 750, 500, 250, 100 bp.
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that HPC2 interacted with the LIM protein KyoT2, and might
in turn form a molecular complex with RBP-J. We also pro-
vided evidence that HPC2 suppressed transactivation of the
RBP-J-dependent promoter by NIC when overexpressed in
cells with KyoT2. Given that KyoT2 binds to RBP-J at the
same site as NIC [17], we suggested that KyoT2 suppressed
the RBP-J-mediated transcription by two ways, namely, com-
petition with transactivators for binding sites and recruitment
of co-suppressors such as RING1 [21] and HPC2 (this study).
RING1 and HPC2 are members of the PcG family proteins
that are parts of a cellular memory system responsible for the
stable inheritance of gene activity [22–24]. The PcG genes have
been ﬁrst identiﬁed in Drosophila as suppressors of the home-
otic gene activity [25], and then it has been proposed that PcG
proteins suppress gene activity via the formation of multimeric
protein complexes (reviewed in [26]). In vertebrate, human
HPC2 can interact with a RING ﬁnger protein RING1 and
other PcG proteins to form a Polycomb repressive complex
[27]. Moreover, it has been reported recently that members
of PcG proteins are also recruited to promoters and suppresses
transcription [28]. In this study, we provided evidence that
HPC2 might be recruited to RBP-J-dependent promoters by
KyoT2, and suppressed their transactivation. However, more
detailed studies are necessary to elucidate whether HPC2 reg-
ulates the Notch pathway upon transactivation, or acts in a
transcriptional memory machinery to maintain the transcrip-
tion status established during Notch signaling.
Although both RING1 and HPC2 possess transcriptional
suppression domains [22,23], the molecular mechanism by
which they suppress RBP-J is unclear. Two mechanisms might
be proposed. One is that HPC2 and/or RING1 are recruited by
KyoT2 to RBP-J associating with RBP-J-dependent promot-
ers, and suppress transcription mediated by RBP-J. Both
HPC2 and RING1 are nuclear-localized proteins, and they
suppress transcription when recruited promoters [23,28]. The
result of the CHIP assay (Fig. 5) favors that at least HPC2
might be recruited to RBP-J-recognizing promoter and sup-
press transcription. However, recent studies have shown that
the PcG protein HPC2 also functions as a SUMO E3 ligase[29], which catalyzes sumoylation of target proteins, and mod-
ify their speciﬁc subcellular locations as well as their functions
[30]. HPC2 may thus also modulate KyoT2 and/or RBP-J
through sumoylation of these proteins, and regulate their func-
tions. Further studies are underway to test this possibility.
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